Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt No Debt
IGXT's Cash to Debt is ranked higher than
84% of the 919 Companies
in the Global Biotechnology industry.

( Industry Median: 16.62 vs. IGXT: No Debt )
IGXT' s 10-Year Cash to Debt Range
Min: 0.07   Max: No Debt
Current: No Debt

Equity to Asset 0.88
IGXT's Equity to Asset is ranked higher than
91% of the 768 Companies
in the Global Biotechnology industry.

( Industry Median: 0.65 vs. IGXT: 0.88 )
IGXT' s 10-Year Equity to Asset Range
Min: -0.4   Max: 0.9
Current: 0.88

-0.4
0.9
Interest Coverage No Debt
IGXT's Interest Coverage is ranked higher than
85% of the 432 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. IGXT: No Debt )
IGXT' s 10-Year Interest Coverage Range
Min: 9999.99   Max: 9999.99
Current: No Debt

F-Score: 3
Z-Score: 19.75
M-Score: -3.52
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -369.01
IGXT's Operating margin (%) is ranked higher than
60% of the 825 Companies
in the Global Biotechnology industry.

( Industry Median: -65.07 vs. IGXT: -369.01 )
IGXT' s 10-Year Operating margin (%) Range
Min: -855   Max: -87.43
Current: -369.01

-855
-87.43
Net-margin (%) -367.25
IGXT's Net-margin (%) is ranked higher than
61% of the 825 Companies
in the Global Biotechnology industry.

( Industry Median: -69.75 vs. IGXT: -367.25 )
IGXT' s 10-Year Net-margin (%) Range
Min: -630   Max: -131.86
Current: -367.25

-630
-131.86
ROE (%) -54.12
IGXT's ROE (%) is ranked higher than
64% of the 870 Companies
in the Global Biotechnology industry.

( Industry Median: -28.10 vs. IGXT: -54.12 )
IGXT' s 10-Year ROE (%) Range
Min: -1461.46   Max: -45.62
Current: -54.12

-1461.46
-45.62
ROA (%) -43.86
IGXT's ROA (%) is ranked higher than
63% of the 920 Companies
in the Global Biotechnology industry.

( Industry Median: -21.69 vs. IGXT: -43.86 )
IGXT' s 10-Year ROA (%) Range
Min: -193.99   Max: -31.59
Current: -43.86

-193.99
-31.59
ROC (Joel Greenblatt) (%) -362.18
IGXT's ROC (Joel Greenblatt) (%) is ranked higher than
69% of the 909 Companies
in the Global Biotechnology industry.

( Industry Median: -217.20 vs. IGXT: -362.18 )
IGXT' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -809.24   Max: -150.21
Current: -362.18

-809.24
-150.21
Revenue Growth (%) -20.60
IGXT's Revenue Growth (%) is ranked higher than
65% of the 648 Companies
in the Global Biotechnology industry.

( Industry Median: -0.90 vs. IGXT: -20.60 )
IGXT' s 10-Year Revenue Growth (%) Range
Min: 0   Max: 35.7
Current: -20.6

0
35.7
EBITDA Growth (%) -27.90
IGXT's EBITDA Growth (%) is ranked higher than
61% of the 619 Companies
in the Global Biotechnology industry.

( Industry Median: -8.10 vs. IGXT: -27.90 )
IGXT' s 10-Year EBITDA Growth (%) Range
Min: 0   Max: 122.4
Current: -27.9

0
122.4
EPS Growth (%) -30.70
IGXT's EPS Growth (%) is ranked higher than
63% of the 649 Companies
in the Global Biotechnology industry.

( Industry Median: -10.20 vs. IGXT: -30.70 )
IGXT' s 10-Year EPS Growth (%) Range
Min: 0   Max: 141
Current: -30.7

0
141
» IGXT's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with IGXT

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Insider Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 5.22
IGXT's P/B is ranked higher than
74% of the 978 Companies
in the Global Biotechnology industry.

( Industry Median: 5.71 vs. IGXT: 5.22 )
IGXT' s 10-Year P/B Range
Min: 5.33   Max: 117
Current: 5.22

5.33
117
P/S 44.84
IGXT's P/S is ranked higher than
59% of the 978 Companies
in the Global Biotechnology industry.

( Industry Median: 20.23 vs. IGXT: 44.84 )
IGXT' s 10-Year P/S Range
Min: 5.83   Max: 58.5
Current: 44.84

5.83
58.5
EV-to-EBIT -10.73
IGXT's EV-to-EBIT is ranked lower than
52% of the 978 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. IGXT: -10.73 )
IGXT' s 10-Year EV-to-EBIT Range
Min: 0   Max: 0
Current: -10.73

Current Ratio 8.88
IGXT's Current Ratio is ranked higher than
88% of the 917 Companies
in the Global Biotechnology industry.

( Industry Median: 3.97 vs. IGXT: 8.88 )
IGXT' s 10-Year Current Ratio Range
Min: 0.66   Max: 11.6
Current: 8.88

0.66
11.6
Quick Ratio 8.88
IGXT's Quick Ratio is ranked higher than
89% of the 917 Companies
in the Global Biotechnology industry.

( Industry Median: 3.81 vs. IGXT: 8.88 )
IGXT' s 10-Year Quick Ratio Range
Min: 0.66   Max: 11.6
Current: 8.88

0.66
11.6

Valuation & Return

vs
industry
vs
history
Price/Net Cash 6.71
IGXT's Price/Net Cash is ranked higher than
89% of the 978 Companies
in the Global Biotechnology industry.

( Industry Median: 86.53 vs. IGXT: 6.71 )
IGXT' s 10-Year Price/Net Cash Range
Min: 8   Max: 32.25
Current: 6.71

8
32.25
Price/Net Current Asset Value 6.71
IGXT's Price/Net Current Asset Value is ranked higher than
88% of the 978 Companies
in the Global Biotechnology industry.

( Industry Median: 52.38 vs. IGXT: 6.71 )
IGXT' s 10-Year Price/Net Current Asset Value Range
Min: 6.4   Max: 52.5
Current: 6.71

6.4
52.5
Price/Tangible Book 5.22
IGXT's Price/Tangible Book is ranked higher than
80% of the 978 Companies
in the Global Biotechnology industry.

( Industry Median: 9.10 vs. IGXT: 5.22 )
IGXT' s 10-Year Price/Tangible Book Range
Min: 5.33   Max: 95
Current: 5.22

5.33
95
Forward Rate of Return (Yacktman) -28.42
IGXT's Forward Rate of Return (Yacktman) is ranked higher than
66% of the 759 Companies
in the Global Biotechnology industry.

( Industry Median: -10.76 vs. IGXT: -28.42 )
IGXT' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 33.1   Max: 97.3
Current: -28.42

33.1
97.3

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Traded in other countries:IGX.Canada
IntelGenx Technologies Corp. is a drug delivery company, that develops novel oral immediate release and controlled-release products for the branded and generic pharmaceutical market.
» More Articles for OTCPK:IGXT

Headlines

Articles On GuruFocus.com
No related article found.

More From Other Websites
INTELGENX TECHNOLOGIES CORP. Files SEC form 8-K, Other Events Sep 17 2014
IntelGenx to Present at Singular Research 9th Annual Best of the Uncovereds Conference Sep 17 2014
INTELGENX TECHNOLOGIES CORP. Files SEC form 8-K, Other Events Aug 21 2014
IntelGenx to Present at the Rodman & Renshaw Global Investment Conference Aug 21 2014
INTELGENX TECHNOLOGIES CORP. Financials Aug 19 2014
IntelGenx Reports Q2, 2014 Results and Provides Corporate Development Update Aug 07 2014
INTELGENX TECHNOLOGIES CORP. Files SEC form 10-Q, Quarterly Report Aug 07 2014
IntelGenx to Host Management Call Jul 18 2014
INTELGENX TECHNOLOGIES CORP. Files SEC form 8-K, Termination of a Material Definitive Agreement,... Jul 15 2014
IntelGenx Announces Management Changes Jul 15 2014
INTELGENX TECHNOLOGIES CORP. Files SEC form 10-Q/A, Quarterly Report Jul 02 2014
INTELGENX TECHNOLOGIES CORP. Files SEC form 8-K, Other Events Jul 01 2014
IntelGenx Announces Equity Analyst Coverage by H.C. Wainwright Jul 01 2014
Coverage initiated on IntelGenx by H.C. Wainwright Jun 30 2014
IntelGenx: A Compelling Investment Opportunity Jun 27 2014
INTELGENX TECHNOLOGIES CORP. Files SEC form 8-K, Other Events May 21 2014
RedHill Biopharma, IntelGenx report positive RHB-103 study results May 21 2014
INTELGENX TECHNOLOGIES CORP. Files SEC form 10-Q, Quarterly Report May 13 2014
INTELGENX TECHNOLOGIES CORP. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders May 08 2014
INTELGENX TECHNOLOGIES CORP. Files SEC form 8-K, Other Events Apr 30 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK